RxDoctor Payments Data

Ashley Rohr, MD

Ophthalmology · Calumet City, ILNPI 1629364708

Payments from drug & device makers

$2,855in general payments, 2019–2025

Across 49 payments — averaging $58.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Glaukos Corporation$450
  • Sight Sciences, Inc.$291
  • Biotissue Holdings Inc.$193
  • Eyevance Pharmaceuticals LLC$159
  • Sun Pharmaceutical Industries Inc.$117
  • plus $354 from 13 others

What the payments were for

  • Travel & lodging$76027%
  • Food & beverage$2,09473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,855 in reported general payments places this provider in the 65th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$139,324
Medicare patients
287
Services billed
1,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost57$36,601
Prednisolone Acetate520$31,462
XiidraLifitegrast17$25,602
RestasisCyclosporine26$19,466
Ketorolac Tromethamine464$13,374
Restasis MultidoseCyclosporine16$12,229
RocklatanNetarsudil Mesylat/Latanoprost24$9,808
Brimonidine Tartrate119$7,350
Ofloxacin318$7,076
CombiganBrimonidine Tartrate/Timolol16$6,734
VyzultaLatanoprostene Bunod13$6,535
Alphagan PBrimonidine Tartrate11$6,126
Cyclosporine18$5,993
Latanoprost435$5,784
RhopressaNetarsudil Mesylate13$4,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan, Alphagan P$26$81,156126 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$39$32,13730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Calumet City

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →